A Leader in Clinical Trials Participation.

Our commitment to clinical trials gives Hawaii’s retinal patients access to the latest technological breakthroughs.

Allergan Clinical Trial

The Retina Institute of Hawaii (RIH) continues its commitment to finding the best possible treatments for retinal diseases and giving its patients access to the newest medications.

RIH is one of forty centers participating in the study of an investigational new drug called AGN-150998, which is being studied as an investigational medication for Wet Age-Related Macular Degeneration (AMD), a leading cause of severe vision loss in the elderly.

In Wet AMD, damage occurs because of the growth of new, leaky blood vessels under the retina. These leaky vessels cause swelling of the macula, the key to clear central vision, as well as other damage including irreversible scarring.

About the Study Drug

The drug under investigation in this study, AGN-150998, is designed to inhibit abnormal vessel growth which may help to resolve retinal swelling.

Patients in this study will be randomized to receive an investigational medication and will then be followed for up to 32 weeks. All office visits, examinations and study medication are at no cost for study participants.

Participation Criteria

To be eligible, patients must meet the following requirements:

  • - Be 50 years of age or older and of Japanese ethnicity (first, second and third generation welcome)
  • - Have age-related macular degeneration
  • - Have not had cataract surgery or Lasik within the past 3 months in the study eye

 

Sign Up Now

 

Our clinical Trial

To register for a free screening or for more information on how to participate in our sponsored Research Study for Wet AMD, please Sign Up Here

To find out if you are a candidate for this study, please discuss with your eye doctors or contact Yuka Koinuma of Retina Institute of Hawaii at (808) 294-4238.